SCHEMBL17876000

SCHEMBL17876000

O=S1(=O)Cc2ccc(-c3ccc4oc5ccccc5c4c3)cc2-c2cc(-c3ccc4oc5ccccc5c4c3)ccc2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 4/20 0.45
MEN1 O00255 3/20 0.45
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 2/20 0.45
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
PLA2G2A P14555 4/20 0.40
PLA2G4A P47712 4/20 0.40
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
AHR P35869 2/20 0.38
PLA2G10 O15496 1/20 0.38
CHEK2 O96017 1/20 0.38
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17875995 0.96 MEN1 (0.42) KMT2ASMN1; SMN2MAPTMEN1KDM4E
SCHEMBL17875944 0.95 MEN1 (0.41) KMT2ASMN1; SMN2MAPTMEN1KDM4E
SCHEMBL17876003 0.94 PLA2G2A (0.44) KMT2ASMN1; SMN2MAPTMEN1KDM4E
SCHEMBL17875994 0.91 MEN1 (0.44) KMT2ASMN1; SMN2MAPTMEN1KDM4E
SCHEMBL17875941 0.91 MEN1 (0.38) KMT2ASMN1; SMN2MAPTMEN1KDM4E
SCHEMBL17876002 0.91 MEN1 (0.38) KMT2ASMN1; SMN2MAPTMEN1KDM4E
SCHEMBL17875987 0.90 ALOX5 (0.50) KMT2ASMN1; SMN2MAPTMEN1KDM4E
SCHEMBL17875943 0.89 PLA2G2A (0.41) KMT2ASMN1; SMN2MAPTMEN1KDM4E
SCHEMBL17875960 0.89 PLA2G2A (0.41) KMT2ASMN1; SMN2MAPTMEN1KDM4E
SCHEMBL17876006 0.88 PLA2G2A (0.38) KMT2ASMN1; SMN2MAPTMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10581000-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-03-03 US disclosed
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-06-30 US disclosed
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10581000-B2 Condensed cyclic compound and organic light-emitting device including the same CRY1, CRY2, CCNE2 KMT2A 1757/4885SMN1; SMN2 3237/4885MAPT 2144/4885
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNE2 KMT2A 1757/4885SMN1; SMN2 3237/4885MAPT 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.